{
    "ticker": "BTTX",
    "name": "BioTime, Inc.",
    "description": "BioTime, Inc. is a biotechnology company focused on the development and commercialization of innovative therapies for the treatment of degenerative diseases. Founded in 1990, BioTime is a pioneer in the field of regenerative medicine, leveraging cutting-edge technologies such as stem cell biology and tissue engineering to create novel treatments aimed at addressing age-related conditions and injuries. The company's leading product candidates include a range of stem cell-derived therapies that are in various stages of clinical development, including applications in orthopedics, ophthalmology, and cardiovascular medicine. BioTime is committed to advancing the science of regenerative medicine, with a strong emphasis on ethical practices and patient safety. Through strategic collaborations and partnerships with academic institutions and industry leaders, BioTime aims to accelerate the translation of scientific discoveries into viable therapeutic options that can significantly improve patient outcomes. The company is headquartered in Alameda, California, and has a robust pipeline of products that reflect its innovative approach to tackling some of the most pressing health challenges of our time.",
    "industry": [
        "Biotechnology",
        "Healthcare"
    ],
    "headquarters": "Alameda, California, USA",
    "founded": "1990",
    "website": "https://www.biotimeinc.com",
    "ceo": "Shankar Musunuri",
    "social_media": {
        "twitter": "https://twitter.com/BioTimeInc",
        "linkedin": "https://www.linkedin.com/company/biotime-inc/"
    },
    "investor_relations": "https://investors.biotimeinc.com",
    "key_executives": [
        {
            "name": "Shankar Musunuri",
            "position": "CEO"
        },
        {
            "name": "Lindsay A. Brown",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "OpRegen",
                "Asterias Cell Therapy"
            ]
        },
        {
            "category": "Research Products",
            "products": [
                "Stem Cell Lines",
                "Differentiation Kits"
            ]
        }
    ],
    "seo": {
        "meta_title": "BioTime, Inc. | Innovating Regenerative Medicine",
        "meta_description": "Explore BioTime, Inc., a leader in biotechnology focused on regenerative medicine and stem cell therapies. Discover our innovative product pipeline and commitment to improving patient outcomes.",
        "keywords": [
            "BioTime",
            "Regenerative Medicine",
            "Stem Cells",
            "Biotechnology",
            "Therapeutics"
        ]
    },
    "faq": [
        {
            "question": "What does BioTime focus on?",
            "answer": "BioTime focuses on developing innovative therapies for degenerative diseases using regenerative medicine and stem cell technology."
        },
        {
            "question": "Who is the CEO of BioTime?",
            "answer": "Shankar Musunuri is the CEO of BioTime, Inc."
        },
        {
            "question": "Where is BioTime headquartered?",
            "answer": "BioTime is headquartered in Alameda, California, USA."
        },
        {
            "question": "What are BioTime's main products?",
            "answer": "BioTime's main products include OpRegen and Asterias Cell Therapy, alongside various stem cell research products."
        },
        {
            "question": "When was BioTime founded?",
            "answer": "BioTime was founded in 1990."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "NVTA",
        "BLCM"
    ],
    "related_stocks": [
        "AMGN",
        "REGN",
        "GILD",
        "BMY"
    ]
}